

NSDE

01/2017

ISO 13485

Certified

High Standards / Medical devices / Pharmaceutical products / Pharmaceutical entrepreneur / Medical devices / Medical devices / Medical entrepreneur / Medical entrepreneur / Medical devices / Medical devices / Medical devices / Medical entrepreneur / Me

botiss biomaterials is an innovative, clinically and scientifically driven, biotech company with head office in Zossen / Berlin. The production sites are located in Krems (AT), Sheffield (UK), Dieburg (DE) and Neustadt-Glewe (DE). Our regeneration products are distributed worldwide in about 100

botiss is a manufacturer of medical devices as defined by MDD 93/42/EEC and has implemented a quality management system conforming to EN ISO 13485.

Pharmaceutical entrepreneur according to Section 4 Subsection 18 of the German Medicines Act (AMG) Placement of pharmaceutical products on the market are scientists.

out of 100 botiss employees

In-House Development / Production / Distribution

Our indication-oriented product portfolio (which includes a range of bone-substitute and collagen biomaterials), our continuous research for innovation as well as a wide clinical and scientific network, have led botiss biomaterials to become one of the major companies in the dental regeneration field in recent years.

Regeneration hard tissue soft tissue

INNOVATIVE

PATIENT-TAILORED PRODUCTS + THERAPEUTIC CONCEPT

patients treated world wide (08/2016)

institutions around the world

botiss biomaterials acts as a link between developers, researchers, and clinicians, with a key focus on the everyday-practice experience. This is the driving force that leads us to a continuous development of new materials and to the optimization of established products. In addition, our worldwide cooperation with prominent research centers and key opinion leaders gives further impulse for pioneering clinical solutions and trends in the field of tissue regeneration.

As a future-oriented company, botiss biomaterials invests in cutting-edge

research such as in stem cells and growth factors. We are convinced that the

investigation of the interaction between biomaterials and stem cells and/or

signaling proteins may pave the way for new approaches to develop innovative

www.indication-matrix.com

bonebuilder

for maxresorb®



















maxresorb® inject maxgraft®



2007 | CE mark approval 2008 | establishment 2009



/ maxgraft® cortico

maxgraft® bonering maxgraft®

of botiss medical AG

























CE mark approval for

Jason® membrane





2012 First bone & tissue days in Berlin

2013 Exclusive cooperation with the Charité tissue bank for the dental regeneration

2014 | Pharmaceutical approval for maxgraft® and for maxgraft® bonebuilder

Second bone & tissue days in Berlin with 800 participants

2015 Market launch of maxgraft® cortico

2016 Third bone & tissue days in Berlin with ~ 1.000 participants

www.botiss-academy.com

CE mark approval permamem® scheduled for 2017

Acquisition of Cells+Tissuebank Austria

technologies and products.

his strategy has already proven to be really vorking. Especially the high quality of the products contributes even further.

Prof. Dr. Dr. Anton Sculean, M.Sc. In many cases I use mucoderm® as an

> tissue graft. Due to its high biocompatibility and excellent mechanical properties mucoderm® is perfectly suitable for the tunneling procedure. Moreover, it serves also as an ideal carrier for biologic active substances such as Emdogain or other growth factors.

alternative for connective

botiss biomaterials aims to set new standards and drive innovations. To achieve this, we dedicate particular effort to the organization of high-quality advanced-training programs. For instance, the botiss academy offers several course formats in Germany and abroad with a focus on different topics such as implantology, periodontology and soft tissue regeneration. The success of this approach attracts internationally renowned experts, who then share and discuss their clinical and scientific results.

SCIENCE

Asst. Prof. Stavros Pelekanos

> 100 educational Events organized worldwide by botiss in 2015/16

on-demand Webinars

2002

* Coming soon

CE mark approval for cerabone®

Employed since 2006 in the dental field

around the world

since 2012: 29 bone & tissue days in 19 countries 10 more planned for 2017

Berlin

Germany: 05/2012 / London, UK: 10/2012 / Bangkok, Thailand: 09/2013 / Budapest, Hungary: 09/2013 / Madrid, Spain: 09/2013 / Istanbul, Turkey: 11/2013 / Copenhagen, Denmark: 05/2014 / Bucharest, Romania: 05/2014 / Opatija, Croatia: 05/2014 / Cape Town, South Africa: 06/2014 / Saint Petersburg, Russia: 06/2014 / Berlin, Germany: 09/2014 / Madrid, Spain: 10/2014 / Medellín, Colombia: 02/2015 / Baku, Azerbaijan: 04/2015 / Køge, Denmark: 05/2015 / Bucharest, Romania: 10/2015 / Madrid, Spain: 10/2015 / Hong Kong, China: 12/2015 / Porto, Portugal: 11/2015 / Salzburg, Austria: 12/2015 / Vilnius, Lithuania: 05/2016 / St. Petersburg, Russia: 06/2016 / Warsaw, Poland: 06/2016 / Porto, Portugal: 07/2016 / Cape Town, South Africa: 07/2016 / Berlin, Germany: 09/2016 / Madrid, Spain: 11/2016 / Tehran, Iran: 11/2016

The bone & tissue days are an innovative congress concept with a strong focus on dental hard and soft tissue regeneration. They are characterized by a combination of theoretical clinical-scientific lectures and practically orientated workshops.

ONLINE REGISTRATION

and more information

on upcoming bone & tissue days at

www.boneandtissue.com

Innovation.
Regeneration.
Aesthetics.





Products distributed in Ger

countries world wide

botiss biomaterials GmbH Hauptstr. 28 15806 Zossen / Berlin Germany

Tel.: +49 33769 / 88 41 985 Fax: +49 33769 / 88 41 986

contact@botiss.com facebook: botissdental

www.indication-matrix.com www.boneandtissue.com www.botiss-academy.com

www.botiss.com www.botiss-dental.com

2017/2018 Scheduled market launch in USA, Australia, Brazil